Roche gives up on anticipated 'good cholesterol' drug

Roche's ($RHHBY) once-promising "good cholesterol" drug candidate is now history. The Swiss company stopped development of dalcetrapib after it fell short in a late-stage trial. Coupled with the failure of Pfizer's ($PFE) similar treatment several years ago, the Roche news has raised concerns about drugs under study at Merck ($MRK) and Eli Lilly ($LLY). Report